Please assess the completion status of the following clinical trial:

Trial Title: Chemoembolization for Lung Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Lung, endobronchial, pleural, or mediastinal metastases that are not responding to systemic chemotherapy, and that are not amenable to ablation, resection, or SBRT.~* At least 18 years old.~* ECOG performance status 0 or 1~Exclusion Criteria:~* Primary lung cancer~* \>50% of a lung is replaced with tumor~* Oxygen saturation \<92% on room air~* FEV1 \<60%~* Pulmonary hypertension (diagnosed or suspected on echocardiography, CT, MRI, or direct pressure measurement)~* Recent pulmonary embolism (within 3 months)~* Pulmonary arteriovenous malformation~* Active lung infection (pneumonia, empyema, or lung abscess requiring therapy within 1 month)~* Symptomatic heart failure (dyspnea, volume overload)~* Left bundle branch block (contraindication to pulmonary angiography)~* Renal failure (eGFR \<30 mL/min/1.73m\^2)~* Pregnancy~* Breastfeeding~* Altered mental status that would interfere with consent or follow-up~* Platelets \< 100,000 (after transfusion, if needed)~* INR\>2 (after transfusion, if needed)~* Hemoglobin \<7 (after transfusion, if needed)~* Hyperthyroidism (contraindication to lipiodol)~* Planned radioactive iodine imaging or therapy (contraindication to lipiodol)~* Allergy to lipiodol or mitomycin~* Allergy to iodinated contrast that can not be treated with steroid / diphenhydramine premedication~* Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lung, Endobronchial, Mediastinal or Pleural Metastases (Type: EXPERIMENTAL): Participants will have unresectable and unablatable lung, endobronchial, mediastinal, or pleural metastases (from any primary) that are not responding to chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).